Ramipril: the pathway in the body

Ramipril is part of the pathway “Ramipril”. This page shows the whole pathway; the station of Ramipril is highlighted.

Where this laboratory value sits: Ramipril — ester precursor, swallowed. Ramipril is swallowed as a capsule. It is not yet the form that acts at the enzyme but a precursor: at one place on the molecule sits an ethyl ester group that has to be cleaved off first. Only in the liver does the inhibitor arise from it. Source 7, 8

In brief

Ramipril is an ACE inhibitor and still an ester precursor itself: only in the liver does ramiprilat arise from it. It lays itself onto the zinc ion in the centre of the angiotensin converting enzyme — and without that zinc the enzyme does not work. Less angiotensin II then forms.

The pathway step by step

Each station states what the compound does there. Three signs: ↑ supplies — builds up or makes available · ↓ depletes — inhibits, consumes or withholds · ↕ both, depending on amount. Behind it stands what the statement rests on: established physiology, observed in studies, or contested. The signs do not grade; they name the direction.

1. Ramipril → Uptake in the gut From the small bowel the substance passes into the blood. The label puts the absorbed share at half or more; food slows the rate of absorption but hardly changes the amount absorbed. With the portal blood it reaches the liver. Source 7, 8↑ supplies Via the small bowel the precursor enters the blood and, with the portal blood, reaches the liver, where conversion occurs. established physiology Source 8, 7
   ⚖ When the balance tips

   too much — If a lot passes over, the precursor rises quickly in the blood and is promptly converted in the liver to ramiprilat, which peaks somewhat later.

   too little — If little passes over, little precursor reaches the liver, and little ramiprilat forms.

   established physiology · Source 7

2. Uptake in the gut → Liver In the liver, esterases cleave off the ethyl ester group. The precursor thereby becomes a compound with two acid groups. The label calls this the cleavage of the ester group in the liver. This produces the inhibitor ramiprilat. Source 7, 8↑ supplies The esterases of the liver turn the precursor into the inhibitor. Without this step hardly any ramiprilat forms. established physiology Source 7, 8
   ⚖ When the balance tips

   too much — If the esterases work briskly, the precursor is converted quickly, and ramiprilat rises early in the blood.

   too little — If the liver works more slowly, for example with reduced liver function, the precursor is converted more slowly, and ramipril itself stays in the blood longer and in larger amounts.

   established physiology · Source 7, 8

3. Liver → Ramiprilat esterases of the liver Ramiprilat is the form that acts at the enzyme. It binds tightly and comes off only slowly, so the binding to the enzyme lasts longer than the substance remains measurable in the blood. It inhibits ACE. Source 7, 8↓ depletes Ramiprilat inhibits ACE: less angiotensin II forms, and bradykinin is broken down more slowly. Because it binds tightly, the inhibition lasts a long time. established physiology Source 8, 7
   ⚖ When the balance tips

   too much — If a lot of ramiprilat is present, for example because the kidney excretes more slowly, a larger share of ACE is inhibited; angiotensin II and aldosterone fall further.

   too little — If little ramiprilat is present, a large share of ACE remains free and keeps making angiotensin II.

   established physiology · Source 8, 7

4. Angiotensinogen → Angiotensin I Renin Renin from the kidney cuts a piece of ten amino acids off angiotensinogen: angiotensin I. This chain does not yet bind to either receptor. Only ACE turns it into the active substance. Source 1↑ supplies Angiotensin I is itself hardly active. It is the starting material from which ACE makes angiotensin II. established physiology Source 1
   ⚖ When the balance tips

   too much — If angiotensin I rises, for example because the kidney releases more renin when little angiotensin II forms, it builds up in front of the enzyme when ACE is inhibited.

   too little — If little angiotensin I is present, ACE has little starting material, and little angiotensin II forms.

   established physiology · Source 1, 8

5. Angiotensin I → Angiotensin II ACE · zinc in the centre, chloride ACE cleaves the last two amino acids off angiotensin I. What remains is angiotensin II. It binds at the AT1 receptor and makes the smooth muscle of the vessels narrower. It also stimulates the release of aldosterone. Source 1, 2, 8↑ supplies Angiotensin II narrows the vessels and stimulates the release of aldosterone. In this way it maintains blood pressure and salt balance. established physiology Source 1, 2
   ⚖ When the balance tips

   too much — If a lot of angiotensin II is present, the vessels narrow, and the adrenal gland releases more aldosterone.

   too little — If little angiotensin II is present, for example with ACE inhibited, the vessels widen, aldosterone release falls, and the kidney releases more renin because the feedback is missing.

   established physiology · Source 1, 8

6. Angiotensin II → Aldosterone AT1 receptor Angiotensin II also binds at the AT1 receptor of the adrenal cortex. The cortex then releases the hormone aldosterone into the blood. Sodium and water then stay in the body. Source 1, 8↑ supplies Aldosterone makes the kidney retain sodium, and water with it, and release potassium. In this way it helps determine how full the vessels are. established physiology Source 1, 5
   ⚖ When the balance tips

   too much — If a lot of aldosterone is present, the collecting duct reclaims more sodium, water follows, and more potassium leaves in the urine.

   too little — If little aldosterone is present, for example with ACE inhibited, more sodium leaves the body, and potassium is released to a lesser extent.

   established physiology · Source 5, 8

7. Aldosterone → Sodium and potassium ENaC, Na-K pump Aldosterone makes the kidney reclaim more sodium in the collecting duct and release more potassium. With less aldosterone both shift; the label describes a small rise of serum potassium. Water follows the sodium. Source 5, 8↑ supplies Through sodium the kidney keeps water in the body and thus the filling of the vessels; through potassium it sets the voltage across cell walls. established physiology Source 5, 1
   ⚖ When the balance tips

   too much — If the kidney reclaims a lot of sodium, water follows, and the vessels are fuller; in exchange, more potassium leaves in the urine.

   too little — If it reclaims little sodium, for example with little aldosterone, more sodium leaves with water, and potassium tends to stay in the blood; the label describes a small rise.

   established physiology · Source 5, 8

8. Bradykinin → Fragments ACE (kininase II) · zinc in the centre The same enzyme also cleaves two amino acids off bradykinin. The fragments no longer fit the B2 receptor. Because of this second job the enzyme carries the second name kininase II. This ends the action of bradykinin. Source 4, 8↓ depletes Breaking it up ends the action of bradykinin: the fragments no longer bind at the B2 receptor. established physiology Source 4, 2
   ⚖ When the balance tips

   too much — If many fragments form because ACE works freely, bradykinin is active only briefly.

   too little — If few form because ramiprilat inhibits ACE, bradykinin stays active at the receptor for longer.

   established physiology · Source 4, 8

Further stations

• Ramipril — ester precursor, swallowed Ramipril is swallowed as a capsule. It is not yet the form that acts at the enzyme but a precursor: at one place on the molecule sits an ethyl ester group that has to be cleaved off first. Only in the liver does the inhibitor arise from it. Source 7, 8↑ supplies The precursor itself is hardly active at the enzyme. It is the form in which the substance passes from the gut into the blood and is carried to the liver. established physiology Source 7, 8
  ⚖ When the balance tips

  too much — If a lot of precursor arrives, the liver has a lot to convert, and more ramiprilat forms.

  too little — If little precursor arrives, little ramiprilat forms, and little inhibitor is present at the enzyme.

  established physiology · Source 7, 8

• Zinc centre of ACE — one zinc ion per domain In the active site of the angiotensin converting enzyme sits a zinc ion, held by two histidines and one glutamate. It holds the water molecule that splits the chain. Ramiprilat lays its acid group onto this zinc. The enzyme then stops. Source 2, 3, 6↑ supplies The zinc ion makes the cleavage possible: it activates the water that breaks the bond in the chain. If ramiprilat occupies it, the enzyme stops. established physiology Source 2, 3
  ⚖ When the balance tips

  too much — If the zinc centres are free and plenty of enzyme is present, angiotensin I is quickly converted to angiotensin II and bradykinin is quickly broken up.

  too little — If the zinc centres are occupied or the zinc is missing from the centre, the enzyme cannot split any chain; hardly any angiotensin II forms, and bradykinin persists longer.

  established physiology · Source 2, 6

• Angiotensinogen — protein from the liver The liver releases angiotensinogen into the blood continuously. It is the common starting chain for the steps that follow. Usually the amount of renin sets the pace. Source 1↑ supplies Angiotensinogen is the store from which renin cuts. It is plentiful in the blood; usually the amount of renin determines how fast angiotensin forms. established physiology Source 1
  ⚖ When the balance tips

  too much — If a lot of angiotensinogen is present, renin can split off more angiotensin I; the pace, however, is usually set by renin.

  too little — If little angiotensinogen is present, less angiotensin I forms even with a lot of renin.

  established physiology · Source 1

• Bradykinin — chain of nine blocks Bradykinin arises in the blood from a precursor once the kallikrein-kinin system starts up. It binds at the B2 receptor and makes vessels wider. ACE breaks it down again quickly. Source 4↑ supplies Through the B2 receptor bradykinin widens the vessels and makes their wall more permeable; nitric oxide and prostaglandins are released in the process. established physiology Source 4
  ⚖ When the balance tips

  too much — If a lot of bradykinin persists, for example with ACE inhibited, vessels widen more, and fluid passes into tissue more easily; the label leaves open what share this has in the action.

  too little — If little bradykinin is present because ACE breaks it up quickly, its vessel-widening action stays brief and local.

  contested · Source 4, 8

What this active substance affects

• Zinc — Sits in the active site of ACE and holds the water for the cleavage; ramiprilat lays its acid group onto this ion Source 2, 3
• Potassium — Aldosterone governs the release of potassium in the collecting duct of the kidney; less aldosterone shifts it Source 5, 8
• Sodium — Aldosterone governs how much sodium the kidney reclaims in the collecting duct; water follows the sodium Source 1, 5

What takes part in these steps

• Histidine — Two histidine side chains hold the zinc ion in place in the active site of ACE; without zinc no cleavage Source 2, 6
• Glutamate — A glutamate side chain is the third anchor of the zinc ion in the active site of ACE; the zinc thus sits firmly Source 2, 6
• Chloride — Chloride ions bind at their own sites on ACE and set how fast the enzyme turns over its chains Source 2

What the prescribing information states

One trial with 1,004 adults on ramipril and 982 on placebo; the observation ran between 6 and 46 months. The prescribing information lists here the reactions that occurred in more than 1 of 100 participants and were more frequent on ramipril than on placebo. The figures apply to this trial.

How to read the table: what matters is the comparison within the row, not the single figure. One point to keep in mind — for this table the prescribing information selected only those reactions that were more frequent on ramipril than on placebo. Anything that occurred equally often in both groups, or more often on placebo, does not appear here at all.

Further reactions have been reported after approval. The prescribing information notes that neither a frequency nor a causal relationship can be derived from such reports; they are therefore not listed here.

Sources

1. Triebel H, Castrop H. The renin angiotensin aldosterone system. Pflugers Arch 2024 · PubMed 38233636
2. Masuyer G, Yates CJ, Sturrock ED et al. Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence. Biol Chem 2014 · PubMed 25205727
3. Natesh R, Schwager SL, Sturrock ED et al. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003 · PubMed 12540854
4. Tang SC, Leung JCK, Lai KN. The kallikrein-kinin system. Contrib Nephrol 2011 · PubMed 21659767
5. Palmer BF. Regulation of Potassium Homeostasis. Clin J Am Soc Nephrol 2015 · PubMed 24721891
6. Cerdà-Costa N, Gomis-Rüth FX. Architecture and function of metallopeptidase catalytic domains. Protein Sci 2014 · PubMed 24596965
7. Meisel S, Shamiss A, Rosenthal T. Clinical pharmacokinetics of ramipril. Clin Pharmacokinet 1994 · PubMed 8137599
8. US prescribing information (United States): Ramipril Capsules, DailyMed, version of 2 Sept 2026, sections 11 Description, 12.1 Mechanism of Action and 12.3 Pharmacokinetics · Prescribing information
9. US prescribing information (United States): Ramipril Capsules, DailyMed, version of 2 Sept 2026, sections 6.1 Clinical Trials Experience and 6.2 Post-Marketing Experience · Prescribing information

Whole pathway: Ramipril

Related pathways

• Candesartan — angiotensinogen

As of 2026-09-25. Draft, written by Claude to schema v2; sources checked in PubMed; expert approval pending
Legal notice Privacy policy All biomarkers